Hemolytic uremic syndrome in a patient with systemic sclerosis treated with cyclosporin A.
The case is presented of a 48-year-old female suffering from diffuse cutaneous systemic sclerosis (diffuse scleroderma) since 8 years, who went into renal failure as part of hemolytic uremic syndrome following 3 weeks' treatment with 3.8 mg/kg cyclosporin A. Hemolytic uremic syndrome has previously been described in transplant patients receiving cyclosporin A. There are also four cases reported in the literature of renal failure developing in middle aged females with diffuse cutaneous systemic sclerosis after short-term use of low dosage cyclosporin A treatment. It is suggested, that it may be wise not to use cyclosporin A to this category of patients, in which it can not be ruled out, that even a low dose therapy may trigger the rapid onset of scleroderma renal crisis or as in our case provoke hemolytic uremic syndrome.
Zachariae
H
H
Department of Dermatology, Marselisborg hospital, Aarhus, Denmark.
Hansen
H E
HE
Olsen
T S
TS
D000208:Acute Disease; D016572:Cyclosporine / Q000009:adverse effects*; D005260:Female; D005355:Fibrosis; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced*; D006801:Humans; D007668:Kidney / Q000473:pathology; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000473:pathology
D016572:Cyclosporine